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Abstract 
Background: A real‑time objective evaluation for the extent of liver steatosis during liver transplantation is currently 
not available. Diffuse reflectance spectroscopy (DRS) rapidly and accurately assesses the extent of steatosis in human 
livers with mild steatosis. However, it is yet unknown whether DRS accurately quantifies moderate/severe steatosis 
and is able to distinguish between micro‑ and macrovesicular steatosis.
Methods: C57BL/6JolaHsd mice were fed wit a choline‑deficient l‑amino acid‑defined diet (CD‑AA) or a choline‑suf‑
ficient l‑amino acid‑defined control diet (CS‑AA) for 3, 8, and 20 weeks. In addition B6.V‑Lepob/OlaHsd (ob/ob) mice 
and their lean controls were studied. A total of 104 DRS measurements were performed in liver tissue ex vivo. The 
degree of steatosis was quantified from the DRS data and compared with histopathological analysis.
Results: When assessed by histology, livers of mice fed with a CD‑AA and CS‑AA diet displayed macrovesicular 
steatosis (range 0–74 %), ob/ob mice revealed only microvesicular steatosis (range 75–80 %), and their lean controls 
showed no steatosis. The quantification of steatosis by DRS correlated well with pathology (correlation of 0.76 in 
CD‑AA/CS‑AA fed mice and a correlation of 0.75 in ob/ob mice). DRS spectra did not distinguish between micro‑ and 
macrovesicular steatosis. In samples from CD‑AA/CS‑AA fed mice, the DRS was able to distinguish between mild and 
moderate/severe steatosis with a sensitivity and specificity of 86 and 81 %, respectively.
Conclusion: DRS can quantify steatosis with good agreement to histopathological analysis. DRS may be useful for 
real‑time objective evaluation of liver steatosis during liver transplantation, especially to differentiate between mild 
and moderate/severe steatosis.
© 2015 Westerkamp et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.
org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
A widely adopted strategy to increase the number of liver 
donors is the use of extended criteria donor (ECD) livers 
[1]. One of the most prevalent conditions to classify a graft 
as ECD liver is hepatic steatosis. According to histopatho-
logical evaluation, steatosis can be categorized in a quali-
tative and quantitative manner. Qualitatively, steatosis is 
subdivided into two different histological patterns: micro- 
and macrovesicular steatosis. Quantitatively, steatosis 
is classified according to the percentage of hepatocytes 
affected by fat vacuoles: mild (less than 30  %), moderate 
(between 30 and 60 %), or severe (above 60 %) [2–4]. How 
steatosis affects graft survival depends on the type and 
degree. Donor livers with microvesicular steatosis (in all 
degrees) and with mild macrovesicular steatosis are suita-
ble for transplantation. On the other hand, livers with mod-
erate and severe macrovesicular steatosis are in most cases 
considered as a contraindication for transplantation due to 
their relation with poor postoperative outcome [2–4].
Given the rising incidence of obesity, the general 
expectation is that more steatotic livers will become 
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available for liver transplantation. However, evaluation 
of the degree and type of steatosis is still a challenge for 
the surgical team during organ procurement procedures. 
Currently, assessment of hepatic steatosis requires a liver 
biopsy. However, processing and examination of the 
biopsy is a logistic challenge during off-hours, when most 
organ procurement procedures take place. Moreover, 
tools for a quick and accurate assessment of the type and 
degree of steatosis are not yet available [4].
Recently, diffuse reflectance spectroscopy (DRS) has 
demonstrated its possibilities to measure lipid concentra-
tion in tissue minimal invasively, accurately and in real-
time [5–9]. In a recent study performed by our group, DRS 
was able to quantify only mild degrees of steatosis [10]. 
However, from a clinical perspective, it is also necessary to 
determine if the DRS is able to discriminate between mild 
and moderate/severe macrovesicular steatosis. In addition, 
the ability of the DRS to discriminate between micro- and 
macrovesicular steatosis is yet unknown.
The aim of the current study is therefore to investigate 
if DRS could quantify moderate and severe steatosis and 
if DRS could differentiate between micro- and macrove-
sicular steatosis. Because (discarded) human donor liv-
ers with mild and moderate steatosis are not available 
in large quantities, we used two well-established mouse 
models (choline-deficient diet and leptin deficiency; ob/
ob) of hepatic steatosis.
Methods
Animals
C57BL/6JolaHsd mice (5–6 weeks old) and B6.V-Lepob/
OlaHsd (ob/ob) mice (9–10  weeks old) were purchased 
from Harlan Laboratories (Boxmeer, the Netherlands). 
Animals were caged in animal rooms with an alternating 
12-h light/dark period and had free access to food and 
water for the duration of the experiment. All procedures 
were approved by and performed in compliance with 
the Institutional Animal Care and Use Committee of the 
University of Groningen (IACUC-RuG).
Experimental design
To induce different stages of hepatic steatosis, the 
C57BL/6JolaHsd mice received a choline-deficient 
l-amino acid-defined (CD-AA) chow diet (no. 518753, 
Dyets Inc., PA, USA) for 3, 8, and 20  weeks. The con-
trol mice were fed with a choline-sufficient l-amino acid 
defined (CS-AA) chow diet (no. 518754, Dyets Inc., PA, 
USA) for the same time periods. The ob/ob mice and 
their lean controls received a standard chow diet (refer-
ence no. 2181 AB Diets, Woerden, the Netherlands) for 
4 weeks (Fig. 1). Each group comprised of 5–7 mice, for a 
total of 52 mice.
After 3, 4, 8 or 20  weeks of feeding, mice were anes-
thetized using a mixture of isoflurane/O2, subjected to a 
hepatectomy, and sacrificed. After the hepatectomy, the 
liver was stored on a petri dish for immediate measure-
ment with the DRS (Fig.  2). Per mouse liver, two liver 
lobes (left median and right upper) were used for ex vivo 
measurements with the optical needle of the DRS system. 
The optical needle was inserted once in each liver lobe. 
Per lobe, five consecutive DRS measurements were per-
formed, which were averaged. Thereafter, a biopsy was 
taken from the specific measurement location for further 
histopathological analysis.
Optical spectroscopy instrumentation and analysis
Recently, the instrumentation and calibration procedure 
of the DRS system was described by Nachabé et  al. [6]. 
In brief, the DRS system consists of a console comprising 
a broadband light source and one spectrometer (Fig. 2). 
The spectrometer resolve light in the near infrared wave-
length range from 1000 up to 1600 nm. Within the opti-
cal needle one fiber was connected to the light source and 
one fiber was connected to the spectrometer to capture 
the diffusely scattered light from the tissue. The diameter 
of the needle is 20 Gauge (0.91 mm) with a fiber distance 
of 0.8 mm. The average tissue volume that is illuminated 
with the needle is roughly 1 mm3. The acquisition time of 
each spectrum was on average 0.2 s.
Analysis of the spectral data has been described pre-
viously [10]. In brief, each cellular component such as 
lipid, hemoglobin or collagen (component of fibrosis) 
has its own intrinsic optical characteristic (spectrum), 
which consists of a combination of absorption and scat-
tering coefficients in a specific wavelength range. From 
our earlier experiments, the spectra of lipid, hemoglobin 
and collagen are identified. Fat and collagen are the dom-
inant chromophores in the wavelength range between 
1100 and 1600  nm, while (oxygenated and deoxygen-
ated) hemoglobin have the dominant chromophores in 
the wavelength range of 500–900 nm [11]. Moreover, the 
absorption coefficients of lipid compared to collagen are 
different [11]. Dependent of the spectra and combina-
tion of absorption and scattering coefficients, the DRS is 
able to estimate the hepatic lipid (fat) content. In addi-
tion, scattering in the wavelength range 1000–1600  nm 
is dominated by Mie scattering. The reduced scattering 
coefficient μs′(λ) is modeled by μs′(λ) = α λ−b where λ 
is the wavelength and b the Mie-slope [11]. Furthermore, 
it is known that contact pressure of the needle affects 
the absorption, scattering and intensity of the spectra 
[12–15], we performed measurements very thoroughly 
in order to apply similar contact pressure on each liver 
specimen. Spectral characteristics analysis (fitting of the 
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data) was performed with a Matlab software package 
(MathWorks Inc., Natick, MA, USA).
Histological analysis
Biopsy specimens from the optical measurement loca-
tions were first fixed in formalin, then paraffin embedded 
and subjected to standard hematoxylin and eosin (H&E) 
staining. For assessment of macrovesicular steatosis, 
the sections were digitally scanned using a digital whole 
slide scanner (Aperio ScanScope GS, Aperio Technolo-
gies, Vista, CA, USA) at a magnification of 40 (100,000 
pixels/inch). Per section, eight digital images were saved 
as TIFF files. Next, a computer-based image-processing 
algorithm was developed in ImageJ (National Institutes 
of Health, Bethesda, MD, USA) for morphometric cal-
culations of the macrovesicular lipid droplet area, as 
described previously [7]. The lipid droplets were identi-
fied by their shape and diameter. Non-hepatocyte areas 
such as sinusoids, vessels and artifacts (tissue cracks) 
were excluded. Macrovesicular steatosis was enumer-
ated for each picture as the percentage of surface con-
sisting of lipid droplets per total surface area. The 
morphometric calculations with ImageJ were not appli-
cable for microvesicular steatosis and hepatocellular 
ballooning. Assessment of microvesicular steatosis and 
hepatocellular ballooning was therefore performed visu-
ally with light microscopy. Microvesicular steatosis was 
defined as innumerable tiny lipid vesicles that were dif-
fusely distributed and causes a foamy appearance of the 
cytoplasm. In hepatocellular ballooning, no cytoplasmic 
fat vacuoles are present; hepatocytes are swollen due to 
lipid accumulation in nonvesiculated areas [16]. Scoring 
of microvesicular steatosis and ballooning was performed 
in a blind fashion by two independent observers (ACW 
and FB) according to the established scoring method of 
Kleiner et al. [17]. The lipid fraction scored by pathologi-
cal evaluation was considered to be a two dimensional 
analysis of the same three dimensional volume of liver 
tissue analyzed with DRS. To adjust the pathological 
scored lipid fraction to a volume lipid fraction, the patho-
logical lipid fractions were recalculated using the princi-
ple postulated by Weibel et al. [18]. Moreover, it should 
be noticed that between histological scoring and DRS 
analysis an intrinsic difference of 5 % is obtained due to 
that lean mice livers without steatosis also contain some 
intracellular lipids [19]. In order to score DRS analysis as 
positive, the determined fat fraction should be above the 
threshold value of 5 %.
Fig. 1 Overview of the experimental groups and type and grade of hepatic fat content. To induce hepatic steatosis, mice received the choline‑
deficient l‑amino acid‑defined (CD‑AA) diet for 3, 8, and 20 weeks. The control mice were fed with choline‑sufficient l‑amino acid defined (CS‑AA) 
chow diet for the same time periods. The ob/ob (leptin deficient) mice and their lean controls received the standard chow diet for 4 weeks. After 
the specific weeks of diet, DRS measurements were performed in liver tissue ex vivo
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Statistical analysis
Spearman’s rank correlation test was used to examine 
the correlation between the DRS ex vivo measurements 
and the histological quantification of steatosis. Linear 
regression (r2) was used to assess correlations between 
DRS measurements and histological quantification of 
steatosis. The statistical differences between the scatter-
ing parameters were determined using a non-parametric 
Kruskal–Wallis test [20]. P levels smaller than 0.05 were 
considered as statistically significant. Analyses were per-
formed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software Inc., La Jolla, CA, USA).
Results
Histological assessment
Histological evaluation of the liver biopsies of mice in the 
CD-AA diet group showed macrovesicular steatosis in 
the range from 17 to 73 %. The degree of macrovesicular 
steatosis increased with the duration of the diet. In addi-
tion, ballooned hepatocytes were observed in the CD-AA 
diet group with an increased number together with an 
increasing duration of the diet. Mice fed with CS-AA 
diet for 3 weeks displayed no steatosis in their biopsies. 
However, 8 and 20  weeks of CS-AA diet also resulted 
in the development of macrovesicular steatosis and/or 
hepatocellular ballooning but these degrees were lower 
than the CD-AA diet group. The ob/ob mice developed 
exclusively microvesicular steatosis, which was severe 
(range 75–80  %) in all animals. Evaluation of the liver 
biopsies of their lean controls showed no evidence of 
hepatic fat infiltration (Fig. 1).
Figure  3 shows examples of the different types of 
hepatic fat infiltration. The large fat droplets of macrove-
sicular steatosis were predominately present in clusters 
around the central vein. In particular, macrovesicular 
steatosis was not evenly distributed throughout the liver. 
The patterns of microvesicular steatosis as well as hepato-
cellular ballooning were more heterogeneous distributed 
in the liver parenchyma. In addition, Fig. 4 illustrates an 
example of liver biopsy with macrovesicular steatosis, 
ballooning, inflammation, and periportal/perivenular 
fibrosis, which were mainly observed in the late stages of 
the CS-AA and CD-AA diet.
Evaluation of steatosis with DRS
In total, 104 DRS measurements were performed in 104 
hepatic tissue specimens from 52 livers. Examples of 
optical spectra of macrovesicular, microvesicular stea-
tosis, and hepatocellular ballooning are presented in 
Fig. 5a. Lipid cells in fatty liver tissue have an absorption 
Fig. 2 Overview of the DRS system and optical measurement. Panel a set‑up of the DRS system with the optical needle. The diameter of the needle 
is 0.91 mm (20 Gauge) with a fiber distance of 0.8 mm. Panel b ex vivo measurement in mouse liver tissue with DRS needle
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peak around 1200  nm [11]. In all the three fat spectra, 
an inverse peak was observed in the vicinity of 1200 nm. 
However, discrimination between the three different 
spectra was not possible due to similar absorption and 
scattering characteristics of these types of fat around 
1200  nm (see also Fig.  6, where boxplots of scattering 
parameters are presented). Therefore, the DRS system 
was not able to differentiate between types of fat; only the 
total hepatic fat fraction could be measured. Figure  5b 
shows examples of hepatic fat fraction of increasing 
Fig. 3 Overview of normal hepatic mouse tissue and different types of hepatic fat filtration. Panels a, b normal hepatic mouse tissue, panel b is a 
magnification of panel a. Panel c, d macrovesicular steatosis, panel d is a magnification of panel c. Panels e, f microvesicular steatosis, panel f is a 
magnification of panel e. Panels g, h hepatocellular ballooning, panel h is a magnification of panel g. Black arrows point to the central vein. All sec‑
tions are H&E stained. Scale bars in the panels a, c, e, and f indicate 500 μm. Scale bars in the panels b, d, f, and h indicate 50 μm
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severity and the corresponding light spectra of the tissue 
generated with the DRS. Depending on the percentage of 
hepatic fat fraction; a deeper inverse peak in the vicin-
ity of 1200 nm is related to a higher degree of hepatic fat 
infiltration. Additionally, in Fig. 6 boxplots are displayed 
showing the reduced scattering coefficient at 1600  nm 
and the corresponding Mie-slope “b”. Due to the sub-
stantial spread of scattering parameters, both scatter-
ing parameters were not significantly different between 
macrovesicular, microvesicular, and hepatocellular bal-
looning, indicating that it was not possible to differenti-
ate between the three types of hepatic fat based on this 
limited data set.
Figures  7 and 8 shows the correlation coefficients 
between the pathological evaluation of macrovesicular 
and microvesicular steatosis and DRS analysis. Because 
the mouse models differ in patterns of steatosis (mac-
rovesicular versus microvesicular), we were able to 
calculate the Spearman’s rank correlation coefficients 
between the two different patterns of steatosis and the 
total fat fraction analyzed by the DRS. For macrove-
sicular steatosis the Spearman’s rank correlation coeffi-
cient was 0.761 and for microvesicular steatosis 0.747. 
In addition, the overall sensitivity of DRS to identify 
macrovesicular and microvesicular steatosis was 100 % 
(Tables 1, 2). Moreover, the positive predictive value was 
80 % for macrovesicular steatosis and 72 % for microve-
sicular steatosis. Therefore, a high level of agreement 
was observed between pathological evaluation and DRS 
analysis in assessment of the hepatic fat content. On the 
other hand, the specificity of DRS to exclude macro- 
and microvesicular steatosis was 48 % for macrovesicu-
lar and 29  % for microvesicular steatosis, respectively 
(Tables 1, 2). However, it should be noticed that in the 
majority of false positive cases (95  %), hepatocellular 
ballooning was observed in histological analysis. There-
fore, the DRS was still measuring fat, despite no mac-
rovesicular or microvesicular steatosis was observed in 
these cases.   
As separate analysis, we assessed in the CS-AA and 
CD-AA diet group whether the DRS is able to dif-
ferentiate between mild macrovesicular steatosis and 
either moderate/severe macrovesicular steatosis (Fig.  7; 
Table  3). Therefore, we changed the cut-off values for 
sensitivity and specificity calculations to 30  % of mac-
rovesicular steatosis measured by pathological analysis 
and to 30 % of hepatic fat fraction assessed by the DRS. 
Interestingly, above 30  % of macrovesicular steatosis, 
the DRS predicts hepatic fat fraction with a sensitivity of 
86 % and specificity of 81 %.
Discussion
This study demonstrates that DRS quantifies steatosis 
with high accuracy in two mouse models of hepatic stea-
tosis. Using the DRS for assessment of the total hepatic 
fat content showed a good correlation with histological 
evaluation of the total hepatic fat content. In addition, 
the DRS is able to discriminate between mild and moder-
ate/severe macrovesicular steatosis with a high sensitivity 
(86 %) and specificity (81 %). Although DRS can qualify 
steatosis in liver tissue, the DRS was not able to discrimi-
nate between micro- and macrovesicular steatosis.
During the clinical donation procedure, it is neces-
sary to distinguish between mild (0–30  %) and moder-
ate/severe macrovesicular (>30  %) graft steatosis. As 
already described, transplantation of moderate/severe 
macrovesicular steatotic donor livers is related to poor 
postoperative outcome, while transplantation with mild 
macrovesicular steatotic livers is not associated with infe-
rior outcome [2–4]. Our study showed that DRS is able to 
differentiate between isolated mild macrovesicular stea-
tosis and moderate and/or severe macrovesicular steato-
sis with high sensitivity and specificity. So far, there are 
no tools for accurate steatosis measurements available 
that can be performed in real-time [4]. In comparison 
to the currently best measuring methods for steatosis; 
computer tomography (CT), magnetic resonance imag-
ing (MRI), and magnetic resonance spectroscopy (MRS) 
[21–24], DRS analysis is easier and less time-consuming, 
which is beneficial in the short time period of donation. 
Moreover, it is known that surgeon’s accuracy in predict-
ing steatosis is low, especially when macrovesicular ste-
atosis is above 30  % [25, 26]. As consequence, DRS has 
the potential to assist the surgical team with estimating 
the hepatic fat content during the transplantation proce-
dure. Therefore, further research should be focused on 
development of the DRS system in a hand-held optical 
instrument.
Fig. 4 Masson trichrome staining of mouse liver in the CD‑AA diet 
group. Clusters of inflammatory cells are visualized in the dashed 
white circle. White arrows show fibrosis (periportal and perivenular). 
Scale bar indicates 100 μm
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In the current study, DRS analysis was not able to dif-
ferentiate between micro- and macrovesicular steatosis 
and hepatocellular ballooning. Although we hypothe-
sized that the DRS could discriminate between the three 
types of hepatic fat, we did not find significantly differ-
ences in the scattering parameters between the three 
groups. Therefore, the inability to distinguish between 
hepatic fat content may have consequences when the 
DRS is applied in clinical situations. First, micro- and 
macrovesicular steatosis are occasionally simultane-
ously present in donor livers [26, 27]. However, in most 
cases where micro- and macrovesicular steatosis are 
Fig. 5 Examples of spectra measured with the DRS in different types of hepatic fat infiltration and various degrees of steatosis. Panel a the dashed 
lines correspond to the wavelength section (around 1200 nm) for which the spectra are altered by the presence of lipid. Panel b examples of spectra 
of normal hepatic mouse tissue and fatty mice livers with an increasing severity of macrovesicular steatosis. A more prominent inverse peak in the 
light spectrum in the vicinity of 1200 nm is related to a higher fat concentration in the measured tissue. A.u. indicates arbitrary units
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simultaneously present, the amount of microvesicular 
steatosis is quite minimal compared to the amount of 
macrovesicular steatosis [26, 27]. We expect therefore 
that the overestimation of the degree of hepatic fat infil-
tration will be negligible when livers with micro- and 
macrovesicular steatosis are measured with the DRS. 
Secondly, it could also happen that only microvesicular 
steatosis is present in donor livers. Hence, there is a risk 
for a false positive result when a liver with only microve-
sicular steatosis is measured with the DRS. However, the 
presence of only microvesicular steatosis is uncommon 
in potential donor livers [26, 27]. Solely microvesicular 
steatosis is frequently observed in subtypes of acute liver 
failure such as the syndrome of Reye and acute fatty liver 
of pregnancy, due to toxin- or drug-induced impairment 
of the mitochondrial β-oxidation [28]. Consequently, it is 
unlikely livers with only microvesicular steatosis would 
be considered for transplantation and consequently 
would be measured with the DRS.
Another aspect of hepatic fat infiltration is hepato-
cellular ballooning. In our experiment some mice livers 
displayed severe degrees of hepatocellular ballooning. 
Hepatocellular ballooning is an important histologi-
cal feature of nonalcoholic steatohepatitis (NASH) [16]. 
Patients with NASH show in most cases elevated serum 
levels of transaminases and/or alkaline phosphatase [29]. 
These elevated levels of transaminases and/or alkaline 
Fig. 6 Boxplots of the reduced scattering coefficient at 1600 nm and the corresponding Mie‑slope “b” for micro‑ and macrovesicular steatosis, and 
hepatocellular ballooning. Panel a boxplots of the reduced scattering coefficient at 1600 nm. Panel b boxplots representing the Mie‑slope “b”. For 
both scattering parameters, no significant differences were found between micro‑ and macrovesicular steatosis, and hepatocellular ballooning
Fig. 7 Comparison of pathological evaluation of macrovesicular 
steatosis and DRS analysis. Comparison between pathological assess‑
ment and DRS analyses provides a Spearman’s rank correlation coef‑
ficient of 0.761. The solid line represents the linear regression line (r2) 
between pathological evaluation and DRS analysis. The dashed lines 
illustrate the quadrants for the sensitivity and specificity calculations 
above 30 % of macrovesicular steatosis between pathological evalua‑
tion and DRS analysis
Fig. 8 Comparison of pathological analyses of microvesicular steato‑
sis and DRS analysis. Comparison between pathological assessment 
and DRS analyses provides a Spearman’s rank correlation of 0.747. The 
solid line represents the linear regression line (r2) between pathologi‑
cal evaluation and DRS analysis
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phosphatase will be noted when the potential donor 
is screened at the intensive care. Moreover, NASH is 
related to the development of fibrosis. Fibrotic livers 
are mostly enlarged and stiff. These characteristics will 
be observed during assessment of the liver during the 
donation procedure. Therefore, it is likely that livers of 
most of these donors with NASH are declined early in 
the donation procedure. As a result, the risk that livers 
with severe hepatocellular ballooning are measured with 
the DRS will be minimal.
Table 1 Accuracy calculations of  DRS analysis with  respect to  macrovesicular steatosis in  the CD-AA and  CS-AA diet 
groups
The DRS analyses are positive for steatosis when the determined fat fraction value is larger than 5 %
DRS diffuse reflectance spectroscopy
Result pathology positive  
for macrovesicular steatosis
Result pathology negative  
for macrovesicular steatosis
Positive result DRS analyses 57 14 71




Positive predictive value 80 %
Negative predictive value 100 %
Table 2 Accuracy calculations of DRS analysis with respect to microvesicular steatosis in the ob/ob and control mice
The DRS analyses are positive for steatosis when the determined fat fraction value is larger than 5 %
DRS diffuse reflectance spectroscopy
Result pathology positive  
for microvesicular steatosis
Result pathology negative  
for microvesicular steatosis
Positive result DRS analyses 13 5 18




Positive predictive value 72 %
Negative predictive value 100 %
Table 3 Accuracy calculations of  DRS analysis in  the CD-AA and  CS-AA diet groups when  cut-off values are changed 
to 30 % of macrovesicular steatosis measured by pathological evaluation and 30 % of hepatic fat fraction assessed by the 
DRS
The DRS analyses are positive for steatosis when the determined fat fraction value is larger than 5 %
DRS, diffuse reflectance spectroscopy
Result pathology positive for  
moderate/severe macrovesicular steatosis
Result pathology negative for  
moderate/severe macrovesicular steatosis
Positive result DRS analyses 36 8 44




Positive predictive value 82 %
Negative predictive value 85 %
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A limitation of the current study is that we have used 
mouse livers instead of human donor livers. However, 
with respect to C57BL6 mice on a choline-deficient diet, 
it has been shown that these mice are representative 
for human features of fatty liver disease, in particular 
for macro- and microvesicular steatosis [30]. Another 
limitation regarding the DRS is its invasiveness. How-
ever, in our earlier clinical study where we performed 
in 17 patients’ 49 in vivo DRS measurements, no bleed-
ing complications were observed [10]. In addition, the 
diameter of the optical DRS needle is smaller (0.8 mm) 
compared to a general biopsy needle used for liver biop-
sies during surgery (1.6 mm). Therefore, we expect that 
the bleeding risk in liver tissue after DRS measurements 
will be negligible.
Conclusion
In conclusion, the current study demonstrates that DRS 
can quantify steatosis with good agreement compared 
to histopathological analysis. In particular, its feature to 
differentiate accurately and real-time between isolated 
mild and moderate/severe macrovesicular steatosis may 
have clinical relevance. Consequently, further research 
should be focused on the development of the DRS in a 
hand-held device. The DRS system in a hand-held device 
can assists the surgical team in more accurate assessment 
of the hepatic fat content during organ procurement 
procedures.
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